Clinical trials: Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
The incidence and prevalence of IPF increase exponentially with age, and IPF occurs more often in older males. Cigarette smoking and environmental dust exposures are known risk factors for developing IPF.
- Trial name
- NCT01118221
- Testing
- pulmonary rehabilitation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- US Department of Veterans Affairs
Pulmonary Fibrosis
Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
The aim of this trial is to offer continuation of BIBF 1120 treatment for patients with Idiopathic Pulmonary Fibrosis (IPF) who have completed a prior clinical trial with that drug.
- Trial name
- NCT01170065
- Testing
- BIBF 1120
- Where
- 57 sites in Argentina, Australia and 19 more
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).
Assess the safety of CHF10067 (study drug) and any side effects that might be associated with it. The study also evaluated how much of the study drug gets into the bloodstream and how long the body takes to remove it.
- Trial name
- NCT05513950
- Testing
- CHF10067 starting dose -- 1000mg (Cohort A), CHF10067 intermediate dose -- 2000mg (Cohort B), CHF10067 high dose -- 3000mg (Cohort C)
- Where
- 9 sites in North Macedonia, Ukraine and 1 more
- Volunteers
- 52 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease, Asthma
Impact of Air Pollution on Chronic Respiratory Diseases
The aim of this study is to evaluate the impact of air pollution on the occurrence and clinical course of chronic respiratory diseases, and discover new biomarkers from various devices such as CT images that can indicate the…
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT03813810
- Testing
- Non
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Progressive Idiopathic Pulmonary Fibrosis
Management of Progressive Disease in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a prototype of chronic, progressive, and fibrotic lung disease. It has been considered rare, with an incidence estimated to 11.5 cases per 100 000 individuals per year.
- Trial name
- PROGRESSION (NCT03939520)
- Testing
- pirfenidone and nintedanib, pirfenidone or nintedanib
- Where
- 22 sites in France
- Volunteers
- 279 people
- Sponsor
- Hospices Civils de Lyon
Familial Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
Clinical Genetics and Screening for Idiopathic Pulmonary Fibrosis
Background: Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of interstitial lung disease. Between 2% and 20% of patients with IPF have a family history of the disease, which is considered the strongest risk…
- Trial name
- GENESI (NCT06521125)
- Testing
- High resolution Computed Tomography (HRCT) scans of the Chest, Pulmonary Function Testing (PFTs), Digital lung sounds auscultation
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Idiopathic Pulmonary Fibrosis
The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects
A Phase I, Double-blind, Placebo-controlled, Single Oral Dose, Safety, Tolerability, and Pharmacokinetic Study, Incorporating an Evaluation of the Effect of Food on the Pharmacokinetics of HEC68498 in Healthy Male and Female…
- Trial name
- NCT03502902
- Testing
- HEC 68498
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Idiopathic Interstitial Pneumonia, Interstitial Lung Disease
Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease
The study evaluates the safety and the efficacy of the addition of intravenous transplantation of donor bone marrow mesenchymal stem cells in patients with idiopathic interstitial pneumonia or connective tissue disease associated…
- Conditions
- Idiopathic Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT02594839
- Testing
- Bone marrow mesenchymal stem cells
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Idiopathic Pulmonary Fibrosis
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a…
- Trial name
- NCT05195918
- Testing
- EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, EGCG 600 mg + Nintedanib
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Hal Chapman
Idiopathic Pulmonary Fibrosis
Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib
Multi-center, non-interventional, prospective cohort study aiming to enroll 240 Idiopathic Pulmonary Fibrosis patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.
- Trial name
- QUALIFY IPF (NCT03710824)
- Testing
- Nintedanib
- Where
- 10 sites in Greece
- Volunteers
- 180 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer and Idiopathic Pulmonary Fibrosis
Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization
Retrospective inclusion of lung cancers developed in a context of idiopathic pulmonary fibrosis, diagnosed and / or treated in participating centers.
- Trial name
- K-FPI (NCT03486262)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Idiopathic Interstitial Pneumonias
Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias
We hypothesize that a peripheral blood biomarker or biological signature (gene or protein expression pattern) of idiopathic interstitial pneumonias (IIPs) will simplify and improve the accuracy of diagnosis of IIP and diagnose…
- Trial name
- NCT01151527
- Where
- 2 sites in United States
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Duke University
Idiopathic Pulmonary Fibrosis
PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort
The purpose of the PaTH Network IPF Clinician-Patient Partnership Cohort is to use clinical data from electronic health records (EHR) and patient reported outcomes (PRO) to answer questions of clinical importance to patients with…
- Trial name
- NCT02407431
- Where
- 5 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- University of Pittsburgh
Idiopathic Pulmonary Fibrosis
Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions
A Randomized, Open-Label, Two-Period, Double-Crossover Comparative Study on the Pharmacokinetics of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Chinese Subjects under Fed Conditions Primary objective…
- Trial name
- NCT06588517
- Testing
- Pirfenidone Modified-Release Tablets, Pirfenidone Tablets
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF
Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of subcutaneous Interferon gamma-1b.
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease
- Trial name
- NCT00076635
- Testing
- Interferon gamma-1b
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- InterMune
Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease
Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial
The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Trial name
- OPTIMIZE-ILD-2 (NCT07486206)
- Testing
- Standard ILD Follow-Up Pathway, Optimized One-Day ILD Follow-Up Circuit
- Where
- Spain
- Volunteers
- 152 people
- Sponsor
- Hospital de Granollers
Idiopathic Pulmonary Fibrosis
Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal disease characterized by a progressive damage of lung structure and decline in lung function.This study intends to carry out an open, single-center…
- Trial name
- NCT02745184
- Testing
- Lung stem cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai East Hospital
IPF, Fibrosis
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
The purpose of the study is to assess the safety and tolerability of RXC007 when given for 12 weeks (84 days), alone and in combination with nintedanib or pirfenidone.
- Trial name
- NCT05570058
- Testing
- RXC007
- Where
- 31 sites in Austria, Belgium and 6 more
- Volunteers
- 48 people
- Sponsor
- Redx Pharma Ltd
Pulmonary Arterial Hypertension, Interstitial Lung Disease
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance, hemodynamics and quality of life in patients with interstitial lung disease and severe secondary pulmonary arterial hypertension.
- Conditions
- Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT00705133
- Testing
- Treprostinil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rajan Saggar
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With IPF
The purpose of this study is to test cough, dyspnea (shortness of breath), and quality of life (QOL) questionnaires for their accuracy, sensitivity, and ability to reliably measure the severity of cough, breathlessness, and…
- Trial name
- NCT01874223
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University